California Healthline April 15, 2021
Harris Meyer

Chuck Peterson of Omaha, Nebraska, recently experienced a swollen, painful knuckle caused by arthritis. He got a prescription for colchicine.

Doctors have used the drug for treating gout and other rheumatic conditions for well over two centuries.

When Peterson went to the pharmacy, he was shocked to discover that a two-month supply of 120 pills, distributed by Par Pharmaceutical, would cost him $225 out-of-pocket on his Medicare Part D drug plan. Taking it for an additional three months, as his rheumatologist wanted him to do, would cost him nearly $600 under his drug plan.

A dozen years ago, the drug cost about a dime per pill.

“My reaction was ‘goodness gracious,’ or maybe something I couldn’t say in polite company,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
Pfizer hemophilia gene therapy arrives in US to uncertain future
Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread
Bird Flu (H5N1) Explained: Here’s What To Know—And Why Scientists Are Concerned
2023 Had Most Food Recalls Since Start Of COVID-19 Pandemic, Report Finds

Share This Article